P
Paul Ruff
Researcher at University of the Witwatersrand
Publications - 144
Citations - 12372
Paul Ruff is an academic researcher from University of the Witwatersrand. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 30, co-authored 126 publications receiving 10939 citations. Previous affiliations of Paul Ruff include Johannesburg Hospital & Tufts University.
Papers
More filters
Journal ArticleDOI
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Eric Van Cutsem,Claus Henning Köhne,Erika Hitre,J. Zaluski,Chung Rong Chang Chien,A. Makhson,Geert R. D'Haens,Tamás Pintér,Robert Lim,György Bodoky,Jae Kyung Roh,Gunnar Folprecht,Paul Ruff,Christopher Stroh,Sabine Tejpar,Michael Schlichting,Johannes Nippgen,Philippe Rougier +17 more
TL;DR: In this paper, the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer was investigated.
Journal ArticleDOI
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
Jean-Yves Douillard,Kelly S. Oliner,Salvatore Siena,Josep Tabernero,Ronald Burkes,Mario Edmundo Barugel,Yves Humblet,György Bodoky,David Cunningham,Jacek Jassem,Fernando Rivera,Ilona Kocáková,Paul Ruff,Maria Blasinska-Morawiec,Martin Šmakal,Jean-Luc Canon,Mark Rother,Richard Thomas Williams,Alan Rong,Jeffrey Wiezorek,Roger Sidhu,Scott D. Patterson +21 more
TL;DR: Additional RAS mutations predicted a lack of response in patients who received panitumumab-FOLFOX4 treatment, which was consistent with the findings in patients with KRAS mutations in exon 2.
Journal ArticleDOI
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard,Salvatore Siena,Jim Cassidy,Josep Tabernero,Ronald Burkes,Mario Edmundo Barugel,Yves Humblet,György Bodoky,David Cunningham,Jacek Jassem,Fernando Rivera,Ilona Kocáková,Paul Ruff,Maria Blasinska-Morawiec,Martin Šmakal,Jean-Luc Canon,Mark Rother,Kelly S. Oliner,Michael S. Wolf,Jennifer Gansert +19 more
TL;DR: This study demonstrated that panitumumab-FOLFOX4 was well tolerated and significantly improved PFS in patients with WT KRAS tumors and underscores the importance of KRAS testing for patients with mCRC.
Journal ArticleDOI
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Eric Van Cutsem,Josep Tabernero,Radek Lakomy,Hans Prenen,Jana Prausová,Teresa Macarulla,Paul Ruff,Guy van Hazel,Vladimir Moiseyenko,David R. Ferry,Joseph McKendrick,J. Polikoff,Alexia Tellier,Remi Castan,Carmen J. Allegra +14 more
TL;DR: Adverse effects reported with aflibercept combined with FOLFIRI included the characteristic anti-vascular endothelial growth factor effects and also reflected an increased incidence of some chemotherapy-related toxicities.
Journal ArticleDOI
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
Jean-Yves Douillard,Salvatore Siena,Jim Cassidy,Josep Tabernero,Ronald Burkes,Mario Edmundo Barugel,Yves Humblet,György Bodoky,David Cunningham,Jacek Jassem,Fernando Rivera,Ilona Kocáková,Paul Ruff,Maria Blasinska-Morawiec,Martin Šmakal,Jean-Luc Canon,Mark Rother,Kelly S. Oliner,Ying Tian,F. Xu,Roger Sidhu +20 more
TL;DR: In WT KRAS mCRC, PFS was improved, objective response was higher, and there was a trend toward improved OS with panitumumab-FOLFOX4, with significant improvement in OS observed in an updated analysis of survival.